CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

industry. Recent examples of this include rapid pricing deals on the two CAR-T therapies, Novartis’ Kymriah and Gilead’s Yescarta. ... I think you [the industry] and organisations like NICE have a responsibility to foster a relationship that

Latest news

More from news
Approximately 33 fully matching, plus 110 partially matching documents found.

Latest Intelligence

  • “Brexit has been a catalyst for UK clinical research... it’s turbocharged change” “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

    He said it remains a frustration that international perceptions of UK clinical research haven’t kept pace with that change in performance on the ground. ... can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... Manufacturing of CAR-T cell therapies is a highly sophisticated,

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    TALEN is now being deployed most widely in chimeric antigen receptor T cell (CAR-T) therapies, which generally involve harvesting T cells from patients, modifying them to attack tumour cells by ... Companies like Cellectis and partner Allogene are

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    While AZ hasn’t ruled it out completely, the potential poses several challenges. ... It’s very difficult to systemically deliver a CRISPR therapeutic selectively to the right place, especially when there are easier ways of doing that now, such as

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... t the only oral JAK inhibitor developer with its eye on that

More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.